BioCentury
ARTICLE | Company News

Competition looms as Sanofi vaccine gets FDA's first dengue approval in narrow population

May 2, 2019 10:00 PM UTC

FDA approved Sanofi's dengue fever vaccine Dengvaxia in a narrower population than the pharma had sought, reflecting an advisory panel's conclusions in March and leaving the door open to vaccines in Phase III testing to potentially reach broader populations.

Dengvaxia is the first FDA-approved vaccine to prevent dengue disease. The agency approved it only to prevent the disease in people ages 9-16 who have previously been infected with dengue virus and who live in areas where the disease is endemic; Sanofi (Euronext:SAN; NASDAQ:SNY) had sought its approval in people ages 9-45...